Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Introduction: Alzheimer’s disease (AD) is increasing in frequency as the global population ages. Five drugs are approved for treatment of AD, including four cholinesterase inhibitors and an N -methyl-D-aspartate (NMDA)-receptor antagonist. We have an urgent need to find new therapies for AD. Methods: We examined Clinicaltrials.gov, a public website that records ongoing clinical trials. We examined the decade of 2002 to 2012, to better understand AD-drug development. We reviewed trials by sponsor, sites, drug mechanism of action, duration, number of patients required, and rate of success in terms of advancement from one phase to the next. We also reviewed the current AD therapy pipeline. Results: During the 2002 to 2012 observation period, 413 AD trials were performed: 124 Phase 1 trials, 206 Phase 2 trials, and 83 Phase 3 trials. Seventy-eight percent were sponsored by pharmaceutical companies. The United States of America (U.S.) remains the single world region with the greatest number of trials; cumulatively, more non-U.S. than U.S. trials are performed. The largest number of registered trials addressed symptomatic agents aimed at improving cognition (36.6%), followed by trials of disease-modifying small molecules (35.1%) and trials of disease-modifying immunotherapies (18%). The mean length of trials increases from Phase 2 to Phase 3, and the number of participants in trials increases between Phase 2 and Phase 3. Trials of disease-modifying agents are larger and longer than those for symptomatic agents. A very high attrition rate was found, with an overall success rate during the 2002 to 2012 period of 0.4% (99.6% failure). Conclusions: The Clinicaltrials.gov database demonstrates that relatively few clinical trials are undertaken for AD therapeutics, considering the magnitude of the problem. The success rate for advancing from one phase to another is low, and the number of compounds progressing to regulatory review is among the lowest found in any therapeutic area. The AD drug-development ecosystem requires support.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the very high failure rate of clinical trials of AD therapeutics (of ~99.6%), many of which were successful in preclinical testing using these animal models [6, 27, 139]”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“New AD drug development has faced many obstacles, including high monetary and time costs and high failure rates in preclinical and clinical trials (Cummings et al., 2014;Yiannopoulou et al., 2019).”
From Drug repurposing for Alzheimer’s disease from 2012–2022—a 10-year literature review (2023) · cites this paper as Cummings et al., 2014
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Currently approved drugs do little to limit disease progression, and no preventive therapies are available.3,4”
From AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease (2018) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“the success rate of drugs that have gone through clinical trials from 2002 to 2012 show a high failure rate (~ 99.6%) [69]”
From Microglia and monocytes in inflammatory CNS disease: integrating phenotype and function (2022) · cites this paper as [69]
The cited source says what the claim attributes to it.
In the citing paper
“Efforts to develop drugs to treat Alzheimer’s dementia (AD) have a >99% failure rate”
From Exposure to Air Pollution in Relation to Risk of Dementia and Related Outcomes: An Updated Systematic Review of the Epidemiological Literature (2021) · cites this paper as Cummings et al. 2014
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566 · cited 1×
“This is among the lowest for any therapeutic area [13,14].”
Background2013 Alzheimer's disease facts and figures
Alzheimer's Association, Thies, W., & Bleiler, L. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.02.003 · Cited by 3,328
Clinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536 · cited 1×
“This is among the lowest for any therapeutic area [13,14].”
BackgroundThe International Committee of Medical Journal Editors
van der Weyden, M. (2006) · Proceedings of the Workshop on Publishing for Biomedical Journal Editors and Reviewers · doi:10.2349/biij.2.4.e54-13 · Cited by 1,998
Monetary Costs of Dementia in the United States
Hurd, M. D., Martorell, P., Delavande, A., Mullen, K. J., & Langa, K. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmsa1204629 · Cited by 1,484 · cited 1×
“economy than cardiovascular disease or cancer [31].”
2012 Alzheimer's disease facts and figures Alzheimer's Association ∗
Thies, W., & Bleiler, L. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.02.001 · Cited by 982
Donepezil and memantine for moderate-to-severe Alzheimer's disease
Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A., Dening, T., Findlay, D., Holmes, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106668 · Cited by 782 · cited 1×
“2014 receptor AD antagonist (memantine) [3,4].”
Alzheimer's Disease and the Amyloid Cascade Hypothesis: A Critical Review
Reitz, C. (2012) · International Journal of Alzheimer's Disease · doi:10.1155/2012/369808 · Cited by 376 · cited 1×
“neurobiology of AD, and use of combinations of therapies may provide new approaches to AD therapy [24-26].”
BackgroundMullane, K., & Williams, M. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.11.014 · Cited by 213 · cited 1×
“Many failures in AD drug development have occurred, with both small molecules and immunotherapies failing to show a drug/placebo difference or having unacceptable toxicity [5-8].”
Background
Research works printed but not linked: 4
- Food and Drug Administration: Guidance for Industry: Information Program on Clinical Trials for Serious or Life-threatening Disease and Conditions. 2002, Bethesda, MD: US Department of Health and Human Services, Food and Drug Administration
- Food and Drug Administration: Guidance for Industry: Information Program on Clinical Trials for Serious or Life-threatening Disease and Conditions. 2004, Bethesda: US Department of Health and Human Services, Food and Drug Administration
- Getz K, Lamberti MJ: 89% of trials meet enrollment, but timelines slip, half of sites under-enroll. Tufts Cent Study Drug Dev. 2013, 15: 1-4.
- DiMasi JA: Clinical success rates for new cancer drugs double while more enter testing. Tufts Center Study Drug Dev Impact Rep. 2013, 15: 1-4.
Cited by
Items 401–500 of 1,003
Wiciński, M., Domanowska, A., Wódkiewicz, E., & Malinowski, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082749 · Cited by 57
Khalil, K., Mamun, M. M. R. K., Sherif, A., Elsersy, M. S., Imam, A. A.-A., Mahmoud, M. M. E. A., & Alsabaan, M. (2023) · Sensors · doi:10.3390/s23198272 · Cited by 59
“AD is the most prevalent form of dementia; nevertheless, despite the expenditure of billions of dollars on research, there are no drugs available that can treat the disease at this time [5].”
BackgroundHua, X., Ching, C. R. K., Mezher, A. F., Gutman, B. A., Hibar, D. P., Bhatt, P. R., Leow, A., Jack, C. R., Bernstein, M. A., Weiner, M. W., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.09.018 · Cited by 59
“AD drug trials have a high failure rate (Cummings et al., 2014).”
BackgroundBlood-Based Biomarker Candidates of Cerebral Amyloid Using PiB PET in Non-Demented Elderly
Westwood, S., Leoni, E., Hye, A., Lynham, S., Khondoker, M. R., Ashton, N. J., Kiddle, S. J., Baird, A. L., Sáinz‐Fuertes, R., Leung, R., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151155 · Cited by 53
“6% of trials aimed at preventing or reversing the disease between 2002 and 2012 have failed [3].”
BackgroundPreparation of Tetradentate Copper Chelators as Potential Anti‐Alzheimer Agents
Zhang, W., Huang, D., Huang, M., Huang, J., Wang, D., Liu, X., Nguyen, M., Vendier, L., Mazères, S., Robert, A., et al. (2018) · ChemMedChem · doi:10.1002/cmdc.201700734 · Cited by 52
Lalut, J., Santoni, G., Karila, D., Lecoutey, C., Davis, A., Nachon, F., Silman, I., Sussman, J., Weik, M., Maurice, T., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.10.064 · Cited by 52
Geerts, H., Wikswo, J. P., van der Graaf, P. H., Bai, J. P. F., Gaiteri, C., Bennett, D. A., Swalley, S. E., Schuck, E. L., Kaddurah‐Daouk, R., Tsaioun, K., et al. (2019) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12478 · Cited by 56
“In AD the situation is even worse, with more than 240 clinical development projects having failed since the approval of the last medication in 2004.(6) This particularly low success”
BackgroundTechnological Peer Pressure and Product DisclosurePreprint
CAO, S. S., Ma, G., Tucker, J. W., & Wan, C. (2016) · SSRN Electronic Journal · doi:10.2139/ssrn.2741991 · Cited by 52
Pickart, L., Vasquez-Soltero, J., & Margolina, A. (2017) · Brain Sciences · doi:10.3390/brainsci7020020 · Cited by 51
“Over 99% of investigational drugs, participating in over 200 clinical trials, failed to receive approval for the treatment of Alzheimer’s disease [1].”
BackgroundBangen, K. J., Initiative, F. T. A. D. N., Clark, A. L., Werhane, M., Edmonds, E. C., Nation, D. A., Evangelista, N., Libon, D. J., Bondi, M. W., & Delano-Wood, L. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150900 · Cited by 51
“Identification of risk factors and prevention targets for Alzheimer’s disease (AD) has become a critical public health concern given its rapidly increasing prevalence [2, 3] coupled with the overwhelming failure of clinical trials designed to modify risk [4].”
Calcium-Sensing Receptors of Human Neural Cells Play Crucial Roles in Alzheimer's Disease
Chiarini, A., Armato, U., Liu, D., & Dal Prà, I. (2016) · Frontiers in Physiology · doi:10.3389/fphys.2016.00134 · Cited by 51
“…test of clinical trials (reviewed in Han et al., 2015); and (iii) most previous clinical trials of candidate anti-AD drugs recruited patients already at the symptomatic stage of EOFAD or LOAD, viz. their cognitive cortical areas had already undergone irretrievable damage (Cummings et al., 2014).”
BackgroundResultAssociation between Human Blood Metabolome and the Risk of Alzheimer's Disease
Sun, L., Guo, D., Jia, Y., Shi, M., Yang, P., Wang, Y., Liu, F., Chen, G., Zhang, Y., & Zhu, Z. (2022) · Annals of Neurology · doi:10.1002/ana.26464 · Cited by 65
Projecting Burden of Dementia in Spain, 2010–2050: Impact of Modifying Risk Factors
Soto-Gordoa, M., Arrospide, A., Moreno-Izco, F., Martínez-Lage, P., Castilla, I., & Mar, J. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-150233 · Cited by 51
“Unfortunately, approved drugs for dementia have small effect sizes, and a number of disease-modifying treatments have repeatedly failed to show any efficacy [4].”
BackgroundPhysiological and Pathological Factors Affecting Drug Delivery to the Brain by Nanoparticles
Islam, Y., Leach, A. G., Smith, J. A., Pluchino, S., Coxon, C. R., Sivakumaran, M., Downing, J. E., Fatokun, A. A., Teixidò, M., & Ehtezazi, T. (2021) · Advanced Science · doi:10.1002/advs.202002085 · Cited by 57
Be open about drug failures to speed up research
Alteri, E., & Guizzaro, L. (2018) · Nature · doi:10.1038/d41586-018-07352-7 · Cited by 50
Hajjo, R., Sabbah, D. A., Abusara, O. H., & Bawab, A. Q. A. (2022) · Diagnostics · doi:10.3390/diagnostics12122975 · Cited by 62
Varma, V. R., Desai, R. J., Navakkode, S., Wong, L., Anerillas, C., Loeffler, T., Schilcher, I., Mahesri, M., Chin, K., Horton, D. B., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01912-0 · Cited by 53
“INTRODUCTION Advances in understanding the basic biology of Alzheimer’s Disease (AD) have not translated into effective treatments [1].”
BackgroundSampaio, C., Borowsky, B., & Reilmann, R. (2014) · Movement Disorders · doi:10.1002/mds.26021 · Cited by 54
“Recently, the Alzheimer’s disease (AD) arena has been the most active in these types of decisions given that the high rate of phase III failures suggests that the decision-making processes have been flawed.(18) In HD, there are three clinical developments on the brink of making phase II to III decisions.”
BackgroundPharmacogenetic Considerations in the Treatment of Alzheimer’s Disease
Cacabelos, R., Torrellas, C., Teijido, Ó., & Carril, J. C. (2016) · Pharmacogenomics · doi:10.2217/pgs-2016-0031 · Cited by 54
A biosensor-based framework to measure latent proteostasis capacity
Wood, R. J., Ormsby, A. R., Radwan, M., Cox, D., Sharma, A. A., Vöpel, T., Ebbinghaus, S., Oliveberg, M., Reid, G. E., Dickson, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02562-5 · Cited by 49
Pisani, L., Iacobazzi, R. M., Catto, M., Rullo, M., Farina, R., Denora, N., Cellamare, S., & Altomare, C. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.10.016 · Cited by 53
Fanizza, F., Campanile, M., Forloni, G., Giordano, C., & Albani, D. (2022) · Journal of Tissue Engineering · doi:10.1177/20417314221095339 · Cited by 58
Paranjpe, M. D., Belonwu, S., Wang, J. K., Oskotsky, T., Gupta, A., Taubes, A., Zalocusky, K. A., Paranjpe, I., Glicksberg, B. S., Huang, Y., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.735611 · Cited by 49
Binder, J., Ursu, O., Bologa, C., Jiang, S., Maphis, N., Dadras, S., Chisholm, D., Weick, J., Myers, O., Kumar, P., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03068-7 · Cited by 49
Barbera, L. L., Nobili, A., Cauzzi, E., Paoletti, I., Federici, M., Saba, L., Giacomet, C., Marino, R., Krashia, P., Melone, M., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00580-6 · Cited by 50
The application of lipidomics to biomarker research and pathomechanisms in Alzheimer's disease
Wong, M. W. K., Braidy, N., Poljak, A., & Sachdev, P. S. (2016) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000303 · Cited by 51
Doan, N. T., Engvig, A., Persson, K., Alnæs, D., Kaufmann, T., Rokicki, J., Córdova‐Palomera, A., Moberget, T., Brækhus, A., Barca, M. L., et al. (2017) · Scientific Reports · doi:10.1038/srep45131 · Cited by 57
Geifman, N., Kennedy, R., Schneider, L. S. S., Buchan, I. E., & Brinton, R. D. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0332-0 · Cited by 55
“Background Despite substantial investments in research to find better Alzheimer’s disease (AD) therapies, most drug development efforts end in failure [1–3]; to date, there are no generally effective therapies for AD [1].”
BackgroundClinical Pharmacokinetics and Pharmacodynamics of Drugs in the Central Nervous System
Srinivas, N., Maffuid, K., & Kashuba, A. D. M. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0632-y · Cited by 59
Mechanisms of Risk Reduction in the Clinical Practice of Alzheimer’s Disease Prevention
Schelke, M. W., Attia, P., Palenchar, D. J., Kaplan, B., Mureb, M., Ganzer, C. A., Scheyer, O., Rahman, A., Kachko, R., Krikorian, R., et al. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00096 · Cited by 56
“For example, the potential disease-modifying agents may have been administered too late in the disease process (Cummings et al., 2014); targeting amyloid alone is not sufficient to modify disease (i.e., other pathogenic mechanisms must also be targeted); or amyloid is a sequelae, rather than a…”
BackgroundHigh-Throughput Screening at the Membrane Interface Reveals Inhibitors of Amyloid-β
Cox, S. J., Lam, B., Prasad, A., Marietta, H. A., Stander, N. V., Joel, J. G., Sahoo, B. R., Guo, F., Stoddard, A. K., Ivanova, M. I., et al. (2020) · Biochemistry · doi:10.1021/acs.biochem.0c00328 · Cited by 49
The Environment Is a Key Factor in Determining the Anti-Amyloid Efficacy of EGCG
Šneideris, T., Sakalauskas, A., Sternke‐Hoffmann, R., Peduzzo, A., Žiaunys, M., Buell, A. K., & Smirnovas, V. (2019) · Biomolecules · doi:10.3390/biom9120855 · Cited by 50
Stem Cell Therapy for Alzheimer’s Disease
Han, F., Bi, J., Qiao, L., & Arancio, O. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-4370-8_4 · Cited by 53
Lee, H. W., Kim, S. Y., Jo, Y., Kim, Y. J., Ye, B. S., & Yu, Y. M. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1137197 · Cited by 51
“Despite constant efforts to develop new drugs, the complexity of pathologies has left no promising treatments for AD (Cummings et al., 2014; Bachurin et al., 2017).”
BackgroundCRISPR/Cas9 genome editing for neurodegenerative diseases
Nojadeh, J. N., Eryilmaz, N. S. B., & Ergüder, B. İ. (2023) · EXCLI journal · doi:10.17179/excli2023-6155 · Cited by 75
“However, despite numerous attempts to develop disease-modifying treatments using animal models of the disease, there have been many failures (Cummings et al., 2014; Galimberti and Scarpini, 2011).”
BackgroundNeuroimaging biomarkers in Alzheimer’s disease and other dementias
Villemagne, V. L., & Chételat, G. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.01.004 · Cited by 59
Opportunities and challenges in developing relevant animal models for Alzheimer’s disease
Felice, F. G. D., & Munoz, D. P. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.01.006 · Cited by 52
“Indeed, of 244 unique compounds tested in humans since 2002, only memantine, an NMDA receptor antagonist, has safely translated into AD clinical practice, but with modest effectiveness in promoting cognitive improvement (Cummings et al., 2014).”
BackgroundLi, Q., Zeng, J., Su, M., He, Y., & Zhu, B. (2018) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2018.01.007 · Cited by 50
Elia, C., Losurdo, M., Malosio, M. L., & Coco, S. (2019) · BioEssays · doi:10.1002/bies.201800199 · Cited by 53
Luo, Y., Yang, W., Li, N., Yang, X., Zhu, B., Wang, C., Hou, W., Wang, X., Wen, H., & Tian, X. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00134 · Cited by 51
Role of Intracellular Amyloid β as Pathway Modulator, Biomarker, and Therapy Target
Villarejo, L. G., Bachmann, L., Marks, D., Brachthäuser, M., Geidies, A., & Müller, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094656 · Cited by 53
Pirhaghi, M., Mamashli, F., Moosavi-Movahedi, F., Arghavani, P., Amiri, A., Davaeil, B., Mohammad-Zaheri, M., Mousavi-Jarrahi, Z., Sharma, D., Langel, Ü., et al. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c01167 · Cited by 51
A probe for NIR-II imaging and multimodal analysis of early Alzheimer’s disease by targeting CTGF
Lu, C., Meng, C., Li, Y., Yuan, J., Ren, X., Gao, L., Su, D., Cao, K., Cui, M., Yuan, Q., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49409-4 · Cited by 55
“However, disappointing results from putative disease-modifying therapies of A β have diverted researchers ’ attention to fi nding earlier biomarkers for AD 7 .”
Disease-modifying benefit of Fyn blockade persists after washout in mouse Alzheimer's model
Smith, L. M., Zhu, R., & Strittmatter, S. M. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.11.042 · Cited by 47
“By 2050, Alzheimer's disease is projected to account for 43% of adult deaths in the United States (Weuve et al., 2014).”
Influentialβ-Amyloid Peptide: the Cell Compartment Multi-faceted Interaction in Alzheimer’s Disease
Picone, P., Nuzzo, D., Giacomazza, D., & Carlo, M. D. (2019) · Neurotoxicity Research · doi:10.1007/s12640-019-00116-9 · Cited by 54
Arduino, I., Iacobazzi, R. M., Riganti, C., Lopedota, A., Perrone, M. G., Lopalco, A., Cutrignelli, A., Cantore, M., Laquintana, V., Franco, M., et al. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.120011 · Cited by 48
Therapeutic Strategies to Reduce the Toxicity of Misfolded Protein Oligomers
Kreiser, R. P., Wright, A. K., Block, N. R., Hollows, J. E., Nguyen, L. T., LeForte, K., Mannini, B., Vendruscolo, M., & Limbocker, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228651 · Cited by 51
“By increasing our understanding of the mechanisms of action of candidate compounds targeting oligomers, we anticipate that it will become possible to develop more clinically relevant therapeutics in comparison to the numerous ones described thus far that target non-specifically the protein aggregation reaction and hav…”
BackgroundAssociation of CSF Aβ 38 Levels With Risk of Alzheimer Disease–Related Decline
Cullen, N., Janelidze, S., Palmqvist, S., Stomrud, E., Mattsson, N., Hansson, O., & Initiative, A. D. N. (2021) · Neurology · doi:10.1212/wnl.0000000000013228 · Cited by 57
The aging immune system in Alzheimer’s and Parkinson’s diseases
Heavener, K. S., & Bradshaw, E. M. (2022) · Seminars in Immunopathology · doi:10.1007/s00281-022-00944-6 · Cited by 55
“Clinical trials for new drugs have not seen significant results in alleviating the disease [25].”
BackgroundLogsdon, B. A., Perumal, T. M., Swarup, V., Wang, M., Funk, C., Gaiteri, C., Allen, M., Wang, X., Dammer, E., Srivastava, G., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/510420 · Cited by 44
“Alzheimer’s Disease (AD) is a debilitating neurodegenerative disease affecting more than 5 million Americans for which we lack effective long-term disease-modifying therapeutic strategies (Cummings et al., 2014).”
BackgroundHtrA1 Proteolysis of ApoE In Vitro Is Allele Selective
Chu, Q., Diedrich, J. K., Vaughan, J. M., Donaldson, C. J., Nunn, M. F., Lee, K.-F., & Saghatelian, A. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b03463 · Cited by 46
Moss, D. E., & Perez, R. G. (2021) · Current Alzheimer Research · doi:10.2174/1567205018666211215150547 · Cited by 49
“Regardless of the mechanism of action, the consistent benefits of AChE inhibitor therapy reviewed here offer unparalleled hope as compared to the prior failed clinical trials of other agents [4,5].”
ResultRakotoarisoa, M., Angelov, B., Drechsler, M., Nicolas, V., Bizien, T., Gorshkova, Y. E., Deng, Y., & Angelova, A. (2022) · Smart Materials in Medicine · doi:10.1016/j.smaim.2022.03.001 · Cited by 52
Epidemiology of neurodegenerative diseases in the East African region: A meta-analysis
Onohuean, H., Akiyode, A. O., Akiyode, O. O., Igbinoba, S. I., & Alagbonsi, A. I. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.1024004 · Cited by 53
“Due to the current lack of availability of effective NDs-modifying medications, immediate attempts to limit the disease-increasing projection could focus on disease prevention via interventions to regulate risk factors (97, 98).”
BackgroundCespón, J., Rodella, C., Rossini, P. M., Miniussi, C., & Pellicciari, M. C. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00420 · Cited by 47
“Therefore, the scientific community is currently increasing its effort to diversify pharmacological targets (Cummings et al., 2014) and develop non-pharmacological interventions (Bamidis et al., 2014; Hsu et al., 2015) to treat, prevent, or slow down aging mechanisms that lead to the progression of…”
BackgroundCai, M., Guo, Z., Xing, G., Peng, H., Zhou, L., Chen, H., McClure, M. A., He, L., Xiong, L., He, B., et al. (2019) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000304 · Cited by 52
Schelter, B. O., Shiells, H., Baddeley, T. C., Rubino, C. M., Ganesan, H., Hammel, J., Vuksanović, V., Staff, R. T., Murray, A. D., Bracoud, L., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190772 · Cited by 47
“6% [16], and a further 19 trial failures since 2012 targeting various aspects of pathological processing of amyloid- [17].”
BackgroundBerman, M. H., & Nichols, T. W. (2019) · Photobiomodulation Photomedicine and Laser Surgery · doi:10.1089/photob.2019.4685 · Cited by 48
Genetic Dissection of Alzheimer’s Disease Using Drosophila Models
Jeon, Y., Lee, J., Choi, B., Won, S.-Y., & Cho, K. S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030884 · Cited by 50
Zhang, Y., Liu, Y., Tang, Y., Zhang, D., He, H., Wu, J., & Zheng, J. (2021) · Chemical Science · doi:10.1039/d1sc01133b · Cited by 47
Harnessing Immunoproteostasis to Treat Neurodegenerative Disorders
Golde, T. E. (2019) · Neuron · doi:10.1016/j.neuron.2019.02.027 · Cited by 45
Desai, R. J., Varma, V. R., Gerhard, T., Segal, J., Mahesri, M., Chin, K., Horton, D. B., Kim, S. C., Schneeweiss, S., & Thambisetty, M. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.6567 · Cited by 45
Global Trends in Alzheimer Disease Clinical Development: Increasing the Probability of Success
Sugino, H., Watanabe, A., Amada, N., Yamamoto, M., Ohgi, Y., Kostic, D., & Sanchez, R. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.07.006 · Cited by 48
Pisani, L., Catto, M., Palma, A. D., Farina, R., Cellamare, S., & Altomare, C. (2017) · ChemMedChem · doi:10.1002/cmdc.201700282 · Cited by 45
Autonomic dysfunction in Parkinson disease and animal models
Metzger, J. M., & Emborg, M. E. (2019) · Clinical Autonomic Research · doi:10.1007/s10286-018-00584-7 · Cited by 48
Cuadrado-Tejedor, M., Pérez-González, M., García-Muñoz, C., Muruzabal, D., García-Barroso, C., Rabal, O., Segura, V., Sánchez-Arias, J. A., Oyarzabal, J., & Garcia-Osta, A. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00149 · Cited by 44
“Given the high failure rate in AD drug development, with no new drug having been approved for this diseases since 2003 (Cummings et al., 2014), it is clearly necessary to change the way we approach the search for new AD targets to improve the results obtained in clinical trials.”
BackgroundAudrain, M., Fol, R., Dutar, P., Potier, B., Billard, J.-M., Flament, J., Alves, S., Burlot, M.-A., Dufayet-Chaffaud, G., Bemelmans, A.-P., et al. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0070-y · Cited by 43
“seem to fit well [22, 23].”
Arnerić, S. P., Batrla-Utermann, R., Beckett, L., Bittner, T., Blennow, K., Carter, L., Dean, R., Engelborghs, S., Genius, J., Gordon, M. F., et al. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160573 · Cited by 44
“The FDA has approved the use of three amyloid PET imaging radioligands for the detection of brain amyloid through the regular NDA application process of radiotracers [79].”
BackgroundInfluentialPittsburgh Compound‐B (PiB) binds amyloid β‐protein protofibrils
Yamin, G., & Teplow, D. B. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.13887 · Cited by 44
Apolipoprotein E region molecular signatures of Alzheimer's disease
Kulminski, A. M., Huang, J., Wang, J., He, L., Loika, Y., & Culminskaya, I. (2018) · Aging Cell · doi:10.1111/acel.12779 · Cited by 45
Xu, Y., Zhang, J., Wang, H., Mao, F., Bao, K., Liu, W., Zhu, J., Li, X., Zhang, H., & Li, J. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00357 · Cited by 46
Operationalized definition of older adults with high cognitive performance
Borelli, W. V., Carmona, K. C., Studart‐Neto, A., Nitríni, R., Caramelli, P., & da Costa, J. C. (2018) · Dementia & Neuropsychologia · doi:10.1590/1980-57642018dn12-030001 · Cited by 52
Newby, D., Prieto‐Alhambra, D., Duarte‐Salles, T., Ansell, D., Pedersen, L. H., van der Lei, J., Mosseveld, M., Rijnbeek, P. R., James, G., Alexander, M., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00606-5 · Cited by 47
More Than Selection Effects: Volunteering Is Associated With Benefits in Cognitive Functioning
Kail, B. L., & Carr, D. C. (2020) · The Journals of Gerontology Series B · doi:10.1093/geronb/gbaa101 · Cited by 49
Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer's dementia
Matthews, D. C., Ritter, A. R., Thomas, R. G., Andrews, R. D., Lukic, A. S., Revta, C., Kinney, J. W., Tousi, B., Leverenz, J. B., Fillit, H. M., et al. (2021) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12106 · Cited by 46
Self-citationInhibiting Aβ toxicity in Alzheimer's disease by a pyridine amine derivative
Zhu, Z., Yang, T., Zhang, L., Liu, L., Yin, E., Zhang, C., Guo, Z., Chen, X., & Wang, X. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.02.052 · Cited by 48
Chaves, S., Resta, S., Rinaldo, F., Costa, M., Josselin, R., Gwizdała, K., Piemontese, L., Capriati, V., Pereira-Santos, A. R., Cardoso, S. M., et al. (2020) · Molecules · doi:10.3390/molecules25040985 · Cited by 43
“In spite of all the research performed to understand and treat AD, there has been a high rate of failure in AD drug development programs [2,3].”
BackgroundNeuroprotective Roles of the Reverse Transsulfuration Pathway in Alzheimer’s Disease
Paul, B. D. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.659402 · Cited by 42
“Analysis of clinical trials conducted so far, reveal a preference for non-amyloid targets, which include therapeutics targeting inflammation, synapse and neuronal protection, vascular factors, neurogenesis, and epigenetic modifications (Cummings et al., 2014).”
BackgroundGustavsson, A., Green, C., Jones, R. W., Förstl, H., Simsek, D., de Vulpillieres, F. D. R., Luthman, S., Adlard, N., Bhattacharyya, S., & Wimo, A. B. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.12.005 · Cited by 50
“No new therapy has been approved since 2003, and a recent review identified more than 200 compounds failing in clinical development (phases 1 through 3) since then [4].”
Sánchez, S. M., Abulafia, C., Duarte-Abritta, B., Guevara, M., Castro, M. N., Drucaroff, L. J., Sevlever, G. E., Nemeroff, C. B., Vigo, D. E., Loewenstein, D., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170491 · Cited by 43
“This lack of correlation between A (cid:2) deposition and cognitive symptoms may, in part, explain the failure of several trials of multiple pharmacological agents targeting A (cid:2) deposition, whose development was inspired by the ACH [4].”
Popuri, K., Balachandar, R., Alpert, K., Lu, D., Bhalla, M., Mackenzie, I. R., Hsiung, R. G.-Y., Wang, L., & Beg, M. F. (2018) · NeuroImage: Clinical · doi:10.1016/j.nicl.2018.03.007 · Cited by 41
“The pre-processed images were segmented into the gray matter (GM), white matter (WM) and cerebrospinal fluid (CSF) tissue regions (Dale et al., 1999) using the Freesurfer software package (https://surfer.nmr.mgh.harvard.edu).”
MethodXu, F., He, B., Feng, X., Yan, T., Bi, K., Jia, Y., & Wang, Z. (2018) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2018.051 · Cited by 47
“For the development of anti-AD drugs in the decade of 2002 through 2012, 244 compounds were assessed and the success rate for advancing agents for regulatory approval was only 0.4% (99.6% attrition) (Cummings et al., 2014).”
BackgroundInfluentialPérez-Areales, F. J., Turcu, A. L., Barniol-Xicota, M., Pont, C., Pivetta, D., Espargaró, A., Bartolini, M., De Simone, A., Andrisano, V., Pérez, B., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.07.051 · Cited by 38
“Indeed, AD is one of the therapeutic areas with the highest attrition rates in clinical trials [8,9].”
Optogenetics: implications for Alzheimer’s disease research and therapy
Mirzayi, P., Shobeiri, P., Kalantari, A., Perry, G. L., & Rezaei, N. (2022) · Molecular Brain · doi:10.1186/s13041-022-00905-y · Cited by 50
Rullo, M., Cipolloni, M., Catto, M., Colliva, C., Miniero, D. V., Latronico, T., de Candia, M., Benicchi, T., Linusson, A., Giacchè, N., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01784 · Cited by 41
Henstridge, C. M., Jackson, R. J., Kim, J. M., Herrmann, A. G., Wright, A. K., Harris, S. E., Bastin, M. E., Starr, J. M., Wardlaw, J., Gillingwater, T. H., et al. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0232-0 · Cited by 41
Biophenols pharmacology against the amyloidogenic activity in Alzheimer’s disease
Omar, S. H. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.02.051 · Cited by 46
A New Noncanonical Anionic Peptide That Translocates a Cellular Blood–Brain Barrier Model
Neves-Coelho, S., Eleutério, R. P., Enguita, F. J., Neves, V., & Castanho, M. A. R. B. (2017) · Molecules · doi:10.3390/molecules22101753 · Cited by 54
“Although there are new potential therapeutic molecules being continuously discovered, they present a failure of almost 98% for small molecules and 100% for large molecules, being unable to translocate the blood–brain barrier (BBB) [3,4].”
BackgroundUpadhyay, P., Sadhu, A., Singh, P. K., Agrawal, A., Ilango, K., Purohit, S., & Dubey, G. P. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.11.008 · Cited by 48
Kaushik, R., Morkovin, E. I., Schneeberg, J., Confettura, A. D., Kreutz, M. R., Senkov, O., & Dityatev, A. E. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00411 · Cited by 39
Improving preclinical to clinical translation in Alzheimer's disease research
Sukoff Rizzo, S. J., Masters, A., Onos, K. D., Quinney, S., Sasner, M., Oblak, A., Lamb, B. T., Territo, P. R., & for the MODEL‐AD consortium (2020) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12038 · Cited by 41
“QC and stability testing of the API; and (2) initial PK and PD modeling to inform the dose regimen.”
MethodThe silence of the fats: A MAM’s story about Alzheimer
Agrawal, R. R., Montesinos, J., Larrea, D., Área-Gómez, E., & Pera, M. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105062 · Cited by 47
Raut, S., Patel, R., & Al-Ahmad, A. J. (2021) · Fluids and Barriers of the CNS · doi:10.1186/s12987-020-00235-y · Cited by 41
Yu, F., Salisbury, D., & Mathiason, M. A. (2021) · Journal of Sport and Health Science · doi:10.1016/j.jshs.2020.05.007 · Cited by 40
“Currently, AD cannot be prevented or cured because the majority of drug trials for AD have failed.(2) In contrast, substantial evidence has accumulated and supports the role of exercise in reducing AD risk by 30% to 40%.”
BackgroundGehlot, P., Kumar, S., Vyas, V. K., Choudhary, B. S., Sharma, M., & Malik, R. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.117047 · Cited by 46
Urkon, M., Ferencz, E., Szász, J. A., Szabó, M. I. M., Orbán-Kis, K., Szatmári, S., & Nagy, E. E. (2025) · Pharmaceuticals · doi:10.3390/ph18050614 · Cited by 45
“The disease is indeed the most frequent cause Pharmaceuticals 2025 , 18 , 614 2 of 36 of dementia, affecting approximately 55 million people worldwide (60–70% of all dementia cases) [2], entailing a great economic impact, including healthcare, social care, and research investments [3,4].”
Fujishima, M., Kawaguchi, A., Maikusa, N., Kuwano, R., Iwatsubo, T., Matsuda, H., (ADNI), F. T. J. A. D. N. I., & (J-ADNI), T. J. A. D. N. I. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160621 · Cited by 43
“, acetylcholinesterase inhibitors or N-methyl-D-aspartate receptor antagonists) [10].”
BackgroundMedhat, D., El‐mezayen, H. A., El‐Naggar, M. E., Farrag, A. R. H., Abdelgawad, M. E., Hussein, J., & Kamal, M. H. (2019) · Molecular Biology Reports · doi:10.1007/s11033-019-04907-3 · Cited by 42
Paudel, P., Seong, S. H., Zhou, Y., Park, H. J., Jung, H. A., & Choi, J. S. (2019) · ACS Omega · doi:10.1021/acsomega.9b01557 · Cited by 41
A Novel Neuroregenerative Approach Using ETB Receptor Agonist, IRL-1620, to Treat CNS Disorders
Gulati, A., Hornick, M. G., Briyal, S., & Lavhale, M. S. (2018) · Physiological Research · doi:10.33549/physiolres.933859 · Cited by 42
“During the 2002 to 2012 observation period, 413 AD trials were performed with an overall success rate of 0.4 % (99.6 % failure) (Cummings et al. 2014).”
BackgroundInfluential
Metadata
- Authors
- Cummings, J. L., Morstorf, T., & Zhong, K.
- Affiliations
- Cleveland Clinic (US)
- Touro University Nevada (US)
- Corresponding author
- Cummings, Jeffrey L
- Venue
- Alzheimer's Research & Therapy
- Published
- 2014-07-03
- Volume
- 6
- Issue
- 4
- Pages
- 37-37
- ISSN
- 1758-9193 (ISSN-L)
- PMC
- PMC4095696
- OpenAlex
- W2146249493
- Cited by
- 1,744
- References
- 29
- Citations by year
- 2026: 86 · 2025: 65 · 2024: 113 · 2023: 122 · 2022: 189 · 2021: 193 · 2020: 208 · 2019: 207 · 2018: 200 · 2017: 144 · 2016: 122 · 2015: 79 · 2014: 15
- FWCI
- 79.49
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Alzheimer s Research & Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, drug development pipeline, clinical trials, trial attrition, disease-modifying therapy, immunotherapy, cholinesterase inhibitors, NMDA receptor antagonists, ClinicalTrials.gov, pharmaceutical industry sponsorship
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
